IP Library Granted Patent US 9,499,838
Granted Patent B2
US 9,499,838 · App. 12/140,009 · Granted Nov 22, 2016

Human artificial chromosome containing human antibody λ light chain gene and non-human animal containing the human artificial chromosome capable of genetic transmission

Inventors: Yoshimi Kuroiwa (Sioux Falls, SD); Kazuma Tomizuka (Gunma, JP); Hitoshi Yoshida (San Diego, CA); Isao Ishida (Tokyo, JP)
Assignees: KYOWA HAKKO KIRIN CO., LTD.; E. R. SQUIBB & SONS, L.L.C.
C12N15/8509A01K67/0275A01K67/0278C07K16/00C07K16/243C12N15/87C12N15/90A01K2207/15A01K2217/00A01K2217/05A01K2227/105A01K2267/01A01K2267/0381A61K48/00A61K2039/505C07K2317/21C12N2800/30
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 9,499,838
App. No.
12/140,009
Granted
Nov 22, 2016
Kind
B2
Abstract

The present invention relates to a human artificial chromosome which is genetically transmissible to the next generation with high efficiency and the method for using the same. More specifically, the present invention relates to: a human artificial chromosome in which an about 3.5 Mb to about 1 Mb region containing an antibody λ light chain gene derived from human chromosome 22 is bound to a chromosome fragment which is transmissible to a progeny through a germ line of a non-human animal, said chromosome fragment is derived from another human chromosome; a non-human animal carrying the human artificial chromosome and an offspring thereof; a method for producing the non-human animal; a method for producing a human antibody using the nonhuman animal or an offspring thereof; and a human antibody-producing mouse carrying the human artificial chromosome.

Claims (38)

1. A method for producing a monoclonal antibody, which comprises:

immunizing with a desired antigen, a human antibody-producing mouse which carries (1) a human artificial chromosome in which a SC20 chromosome vector is linked to an about 1 Mb to about 3.5 Mb fragment of human chromosome 22 comprising an unrearranged human antibody λ light chain locus, and (2) an unrearranged human antibody κ light chain locus retained on a KCo5 transgene or on fragment W23 of human chromosome 2 (hCF(2-W23)), wherein at least both alleles of endogenous heavy chain locus and κ light chain locus are disrupted or inactivated, and which expresses a human antibody heavy chain comprising a human antibody Ig γ isotype, a human antibody κ light chain, and a human antibody λ light chain;

producing a hybridoma by fusing a mouse myeloma cell with the a spleen cell derived from the mouse; and

thereby producing a monoclonal antibody comprising human immunoglobulin heavy chains and light chains against the antigen.

2. The method of claim 1 , wherein the unrearranged human antibody κ light chain locus is inserted into a mouse chromosome.

3. The method of claim 1 , which further comprises:

isolating human heavy and light chain antibody genes from the hybridoma;

introducing the human heavy and light chain antibody genes into a cell capable of expressing the human heavy and light chain antibody genes;

culturing the cell under a condition capable of expressing the human heavy and light chain antibody genes; and

thereby producing a monoclonal antibody comprising heavy chains and light chains.

4. The method according to claim 3 , wherein the cell is an animal cell, a yeast cell or an insect cell.

5. The method of claim 1 , wherein the human antibody-producing mouse carries at least 40% of the variable region of the human antibody κ light chain.

6. The method of claim 1 , wherein the human antibody-producing mouse carries all the variable regions of the human antibody heavy chain, the human antibody κ light chain, and the human antibody λ light chain.

7. The method of claim 1 , wherein the human antibody κ light chain locus is retained on hCF(2-W23).

8. The method of claim 1 , wherein the human artificial chromosome is ΔΔHAC.

9. The method of claim 1 , wherein the human artificial chromosome is ΔHAC.

10. The method of claim 8 , wherein 100% of cells of the human antibody-producing mouse retain the human artificial chromosome.

11. The method of claim 1 , wherein the size of the fragment of human chromosome 22 comprising the unrearranged human antibody λ light chain locus is from about 1.2 Mb to about 3 Mb.

12. The method of claim 1 , wherein the size of the fragment of human chromosome 22 comprising the unrearranged human antibody λ light chain locus is from about 1.5 Mb to about 2.5 Mb.

13. The method of claim 1 , wherein the size of the fragment of human chromosome 22 comprising the unrearranged human antibody λ light chain locus is 1.5 Mb.

14. The method of claim 1 , wherein the size of the fragment of human chromosome 22 comprising the unrearranged human antibody λ light chain locus is 2.5 Mb.

15. A method for producing a monoclonal antibody, which comprises:

immunizing with a desired antigen, a human antibody-producing mouse which carries a human artificial chromosome in which a SC20 chromosome vector is linked to an about 1 Mb to about 3.5 Mb fragment of human chromosome 22 comprising an unrearranged human antibody λ light chain locus, wherein at least both alleles of endogenous heavy chain locus and κ light chain locus are disrupted or inactivated, and which expresses a human antibody heavy chain comprising a human antibody Ig γ isotype and a human antibody λ light chain;

producing a hybridoma by fusing a mouse myeloma cell with the a spleen cell derived from the mouse; and

thereby producing a monoclonal antibody comprising human immunoglobulin heavy chains and light chains against the antigen.

16. The method of claim 15 , which further comprises:

isolating human heavy and light chain antibody genes from the hybridoma;

introducing the human heavy and light chain antibody genes into a cell capable of expressing the human heavy and light chain antibody genes;

culturing the cell under a condition capable of expressing the human heavy and light chain antibody genes; and

thereby producing a monoclonal antibody comprising heavy chains and light chains.

17. The method according to claim 16 , wherein the cell is an animal cell, a yeast cell or an insect cell.

18. The method of claim 15 , wherein the human artificial chromosome is ΔΔHAC.

19. The method of claim 15 , wherein the human artificial chromosome is ΔHAC.

20. The method of claim 18 , wherein 100% of cells of the human antibody-producing mouse retain the human artificial chromosome.

21. The method of claim 15 , wherein the size of the fragment of human chromosome 22 comprising the unrearranged human antibody λ light chain locus is from about 1.2 Mb to about 3 Mb.

22. The method of claim 15 , wherein the size of the fragment of human chromosome 22 comprising the unrearranged human antibody λ light chain locus is from about 1.5 Mb to about 2.5 Mb.

23. The method of claim 15 , wherein the size of the fragment of human chromosome 22 comprising the unrearranged human antibody λ light chain locus is 1.5 Mb.

24. The method of claim 15 , wherein the size of the fragment of human chromosome 22 comprising the unrearranged human antibody λ light chain locus is 2.5 Mb.

Assignments (4)
MERGER Recorded Jun 3, 2015
From: MEDAREX, L.L.C.
To: E. R. SQUIBB & SONS, L.L.C.
Reel/Frame 035775/0436 →
MERGER Recorded May 7, 2014
From: MEDAREX, INC.
To: MEDAREX, L.L.C.
Reel/Frame 032836/0250 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Feb 24, 2014
From: KUROIWA, YOSHIMI; TOMIZUKA, KAZUMA; YOSHIDA, HITOSHI; ISHIDA, ISAO
To: KIRIN BEER KABUSHIKI KAISHA; MEDAREX, INC.
Reel/Frame 032279/0655 →
MERGER Recorded Feb 17, 2010
From: KIRIN PHARMA KABUSHIKI KAISHA
To: KYOWA HAKKO KIRIN CO., LTD.
Reel/Frame 023945/0340 →
Priority Claims (1)
JP 2001-142371 · May 11, 2001 · national
Continuity (3)
Continuation 11151227 · Jun 14, 2005
Division 10477471
Related Publication 20080317743A1 · Dec 25, 2008